🇺🇸 Clindamycin Phosphate / Benzoyl Peroxide Gel in United States
10 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 10
Most-reported reactions
- Arthralgia — 1 report (10%)
- Chemical Injury — 1 report (10%)
- Drug Effect Decreased — 1 report (10%)
- Drug Ineffective — 1 report (10%)
- Erythema — 1 report (10%)
- Gastrointestinal Disorder — 1 report (10%)
- Insomnia — 1 report (10%)
- Joint Crepitation — 1 report (10%)
- Neuropathy Peripheral — 1 report (10%)
- Pain Of Skin — 1 report (10%)
Other Dermatology approved in United States
Frequently asked questions
Is Clindamycin Phosphate / Benzoyl Peroxide Gel approved in United States?
Clindamycin Phosphate / Benzoyl Peroxide Gel does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Clindamycin Phosphate / Benzoyl Peroxide Gel in United States?
Watson Laboratories, Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.